Personalized	O
axillary	B:C0193867
dissection	I:C0193867
:	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
of	O
nodal	O
-	I:C3160887
positive	I:C3160887
breast	I:C3160887
cancer	I:C3160887
patients	O
has	O
no	O
significant	O
impact	O
on	O
relapse	O
-	O
free	O
and	O
overall	O
survival	O
.	O

Personalized	O
axillary	O
dissection	I:C0193867
:	O
the	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
of	O
nodal	O
-	I:C3160887
positive	I:C3160887
breast	I:C3160887
cancer	I:C3160887
patients	O
has	O
no	O
significant	O
impact	O
on	O
relapse	O
-	O
free	O
and	O
overall	O
survival	O
.	O

Personalized	O
axillary	O
dissection	I:C0193867
:	O
the	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
of	O
nodal	O
-	I:C3160887
positive	I:C3160887
breast	I:C3160887
cancer	I:C3160887
patients	O
has	O
no	O
significant	O
impact	O
on	O
relapse	O
-	O
free	O
and	O
overall	O
survival	O
.	O

Personalized	O
axillary	O
dissection	I:C0193867
:	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
of	O
nodal	B:C3160887
-	I:C3160887
positive	I:C3160887
breast	I:C3160887
cancer	I:C3160887
patients	O
has	O
no	O
significant	O
impact	O
on	O
relapse	O
-	O
free	O
and	O
overall	O
survival	O
.	O

Sentinel	B:C1522495
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	B:C1522495
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	B:C0005558
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	B:C0178759
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	B:C3160889
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

Sentinel	O
lymph	I:C1522495
node	I:C1522495
(	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
)	O
biopsy	O
has	O
replaced	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
(	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
)	O
for	O
the	O
staging	O
of	O
clinically	O
node	O
-	I:C3160889
negative	I:C3160889
breast	I:C3160889
cancer	I:C3160889
patients	O
(	O
BCP	O
)	O
,	O
demonstrating	O
equivalent	O
survival	O
to	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
while	O
resulting	O
in	O
reduced	O
morbidity	O
.	O

axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
has	O
remained	O
the	O
standard	O
of	O
care	O
for	O
the	O
majority	O
of	O
BCP	O
with	O
clinical	O
axillary	O
metastases	I:C0684830
or	O
metastases	O
found	O
on	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
biopsy	O
.	O

axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
has	O
remained	O
the	O
standard	O
of	O
care	O
for	O
the	O
majority	O
of	O
BCP	O
with	O
clinical	O
axillary	B:C0684830
metastases	I:C0684830
or	O
metastases	O
found	O
on	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
biopsy	O
.	O

axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
has	O
remained	O
the	O
standard	O
of	O
care	O
for	O
the	O
majority	O
of	O
BCP	O
with	O
clinical	O
axillary	O
metastases	I:C0684830
or	O
metastases	B:C0027627
found	O
on	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
biopsy	O
.	O

axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
has	O
remained	O
the	O
standard	O
of	O
care	O
for	O
the	O
majority	O
of	O
BCP	O
with	O
clinical	O
axillary	O
metastases	I:C0684830
or	O
metastases	O
found	O
on	O
Sentinel	B:C1522495
lymph	I:C1522495
node	I:C1522495
biopsy	O
.	O

axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
has	O
remained	O
the	O
standard	O
of	O
care	O
for	O
the	O
majority	O
of	O
BCP	O
with	O
clinical	O
axillary	O
metastases	I:C0684830
or	O
metastases	O
found	O
on	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
biopsy	B:C0005558
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
negative	O
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
positive	O
disease	O
or	O
even	O
in	O
all	O
patients	O
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	B:C1522495
lymph	I:C1522495
node	I:C1522495
-	O
negative	O
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
positive	O
disease	O
or	O
even	O
in	O
all	O
patients	O
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
negative	B:C0205160
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
positive	O
disease	O
or	O
even	O
in	O
all	O
patients	O
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
negative	O
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	B:C1522495
lymph	I:C1522495
node	I:C1522495
-	O
positive	O
disease	O
or	O
even	O
in	O
all	O
patients	O
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
negative	O
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
positive	B:C1446409
disease	O
or	O
even	O
in	O
all	O
patients	O
.	O

More	O
recently	O
,	O
it	O
is	O
debated	O
whether	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
could	O
be	O
avoided	O
not	O
only	O
in	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
negative	O
BCP	O
but	O
also	O
in	O
selected	O
Sentinel	O
lymph	I:C1522495
node	I:C1522495
-	O
positive	O
disease	B:C0012634
or	O
even	O
in	O
all	O
patients	O
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	O
size	I:C0475440
,	O
intrinsic	O
subtypes	O
and	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	O
size	I:C0475440
,	O
intrinsic	O
subtypes	O
and	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	B:C0475440
size	I:C0475440
,	O
intrinsic	O
subtypes	O
and	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	O
size	I:C0475440
,	O
intrinsic	B:C0205102
subtypes	O
and	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	O
size	I:C0475440
,	O
intrinsic	O
subtypes	B:C0449560
and	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

This	O
analysis	O
of	O
pN+	O
BCP	O
shows	O
the	O
impact	O
of	O
the	O
number	O
of	O
excised	O
lymph	O
nodes	I:C0024204
on	O
RFS	O
and	O
OAS	O
adjusted	O
by	O
age	O
,	O
tumor	O
size	I:C0475440
,	O
intrinsic	O
subtypes	O
and	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
.	O

In	O
this	O
retrospective	O
,	O
multicenter	B:C1096776
cohort	O
study	O
,	O
we	O
investigated	O
data	O
from	O
2992	O
pN	O
+	O
primary	O
BCP	O
recruited	O
from	O
17	O
participating	O
certified	O
breast	O
cancer	I:C1516604
centers	I:C1516604
in	O
Germany	O
between	O
2001	O
and	O
2008	O
within	O
the	O
BRENDA	O
study	O
group	O
.	O

In	O
this	O
retrospective	O
,	O
multicenter	O
cohort	O
study	O
,	O
we	O
investigated	O
data	O
from	O
2992	O
pN	O
+	O
primary	O
BCP	O
recruited	O
from	O
17	O
participating	O
certified	O
breast	B:C1516604
cancer	I:C1516604
centers	I:C1516604
in	O
Germany	O
between	O
2001	O
and	O
2008	O
within	O
the	O
BRENDA	O
study	O
group	O
.	O

In	O
this	O
retrospective	O
,	O
multicenter	O
cohort	O
study	O
,	O
we	O
investigated	O
data	O
from	O
2992	O
pN	O
+	O
primary	O
BCP	O
recruited	O
from	O
17	O
participating	O
certified	O
breast	O
cancer	I:C1516604
centers	I:C1516604
in	O
Germany	B:C0017480
between	O
2001	O
and	O
2008	O
within	O
the	O
BRENDA	O
study	O
group	O
.	O

In	O
this	O
retrospective	O
,	O
multicenter	O
cohort	O
study	O
,	O
we	O
investigated	O
data	O
from	O
2992	O
pN	O
+	O
primary	O
BCP	O
recruited	O
from	O
17	O
participating	O
certified	O
breast	O
cancer	I:C1516604
centers	I:C1516604
in	O
Germany	O
between	O
2001	O
and	O
2008	O
within	O
the	O
BRENDA	B:C0021428
study	O
group	O
.	O

The	O
median	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
was	O
17	O
.	O

The	O
median	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
was	O
17	O
.	O

The	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
was	O
neither	O
significant	O
for	O
RFS	O
(	O
p	O
=	O
0.085	O
)	O
nor	O
for	O
OAS	O
(	O
p	O
=	O
0.285	O
)	O
.	O

The	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
was	O
neither	O
significant	O
for	O
RFS	O
(	O
p	O
=	O
0.085	O
)	O
nor	O
for	O
OAS	O
(	O
p	O
=	O
0.285	O
)	O
.	O

Adjustments	O
were	O
made	O
for	O
age	O
,	O
tumor	B:C0475440
size	I:C0475440
and	O
intrinsic	O
subtypes	O
.	O

Adjustments	O
were	O
made	O
for	O
age	O
,	O
tumor	O
size	I:C0475440
and	O
intrinsic	B:C0205102
subtypes	O
.	O

Adjustments	O
were	O
made	O
for	O
age	O
,	O
tumor	O
size	I:C0475440
and	O
intrinsic	O
subtypes	B:C0449560
.	O

The	O
most	O
important	O
significant	O
parameters	O
for	O
RFS	O
were	O
intrinsic	B:C0205102
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
and	O
tumor	O
size	I:C0475440
(	O
p	O
<	O
0.001	O
)	O
and	O
for	O
OAS	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
important	O
significant	O
parameters	O
for	O
RFS	O
were	O
intrinsic	O
subtypes	B:C0449560
(	O
p	O
<	O
0.001	O
)	O
and	O
tumor	O
size	I:C0475440
(	O
p	O
<	O
0.001	O
)	O
and	O
for	O
OAS	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
important	O
significant	O
parameters	O
for	O
RFS	O
were	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
and	O
tumor	B:C0475440
size	I:C0475440
(	O
p	O
<	O
0.001	O
)	O
and	O
for	O
OAS	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
important	O
significant	O
parameters	O
for	O
RFS	O
were	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
and	O
tumor	O
size	I:C0475440
(	O
p	O
<	O
0.001	O
)	O
and	O
for	O
OAS	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
intrinsic	B:C0205102
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
important	O
significant	O
parameters	O
for	O
RFS	O
were	O
intrinsic	O
subtypes	O
(	O
p	O
<	O
0.001	O
)	O
and	O
tumor	O
size	I:C0475440
(	O
p	O
<	O
0.001	O
)	O
and	O
for	O
OAS	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
intrinsic	O
subtypes	B:C0449560
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
RFS	O
and	O
OAS	O
in	O
any	O
subgroup	O
stratified	O
by	O
the	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
RFS	O
and	O
OAS	O
in	O
any	O
subgroup	O
stratified	O
by	O
the	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
.	O

Only	O
for	O
T3	B:C0475374
/	O
T4	O
tumors	I:C0475751
,	O
there	O
is	O
a	O
very	O
small	O
significant	O
advantage	O
of	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
for	O
RFS	O
but	O
not	O
for	O
OAS	O
.	O

Only	O
for	O
T3	O
/	O
T4	B:C0475751
tumors	I:C0475751
,	O
there	O
is	O
a	O
very	O
small	O
significant	O
advantage	O
of	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
for	O
RFS	O
but	O
not	O
for	O
OAS	O
.	O

Only	O
for	O
T3	O
/	O
T4	O
tumors	I:C0475751
,	O
there	O
is	O
a	O
very	O
small	O
significant	O
advantage	O
of	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
for	O
RFS	O
but	O
not	O
for	O
OAS	O
.	O

After	O
adjusting	O
in	O
addition	O
by	O
guideline	O
adherence	O
of	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
(	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
)	O
,	O
intrinsic	O
subtypes	O
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
are	O
the	O
most	O
important	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
parameters	O
for	O
RFS	O
and	O
OAS	O
.	O

After	O
adjusting	O
in	O
addition	O
by	O
guideline	O
adherence	O
of	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
(	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
)	O
,	O
intrinsic	O
subtypes	O
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
are	O
the	O
most	O
important	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
parameters	O
for	O
RFS	O
and	O
OAS	O
.	O

After	O
adjusting	O
in	O
addition	O
by	O
guideline	O
adherence	O
of	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
(	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
)	O
,	O
intrinsic	B:C0205102
subtypes	O
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
are	O
the	O
most	O
important	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
parameters	O
for	O
RFS	O
and	O
OAS	O
.	O

After	O
adjusting	O
in	O
addition	O
by	O
guideline	O
adherence	O
of	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
(	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
)	O
,	O
intrinsic	O
subtypes	B:C0449560
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
are	O
the	O
most	O
important	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
parameters	O
for	O
RFS	O
and	O
OAS	O
.	O

After	O
adjusting	O
in	O
addition	O
by	O
guideline	O
adherence	O
of	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
(	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
)	O
,	O
intrinsic	O
subtypes	O
and	O
guideline	O
-	O
adherent	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
are	O
the	O
most	O
important	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
parameters	O
for	O
RFS	O
and	O
OAS	O
.	O

The	O
number	O
of	O
excised	B:C0728940
lymph	O
nodes	I:C0024204
of	O
pN+	O
BCP	O
neither	O
correlates	O
with	O
RFS	O
nor	O
with	O
OAS	O
.	O

The	O
number	O
of	O
excised	O
lymph	B:C0024204
nodes	I:C0024204
of	O
pN+	O
BCP	O
neither	O
correlates	O
with	O
RFS	O
nor	O
with	O
OAS	O
.	O

Survival	O
of	O
pN+	O
BCP	O
is	O
primarily	O
determined	O
by	O
the	O
biology	O
and	O
the	O
guideline	O
-	O
adherent	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
based	O
on	O
the	O
corresponding	O
intrinsic	O
subtypes	O
.	O

Survival	O
of	O
pN+	O
BCP	O
is	O
primarily	O
determined	O
by	O
the	O
biology	O
and	O
the	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
based	O
on	O
the	O
corresponding	O
intrinsic	B:C0205102
subtypes	O
.	O

Survival	O
of	O
pN+	O
BCP	O
is	O
primarily	O
determined	O
by	O
the	O
biology	O
and	O
the	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
based	O
on	O
the	O
corresponding	O
intrinsic	O
subtypes	B:C0449560
.	O

These	O
results	O
support	O
the	O
omission	O
of	O
a	O
radical	O
axillary	B:C0193867
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
at	O
least	O
for	O
pN	O
+	O
patients	O
scheduled	O
for	O
breast	O
-	I:C0917927
conserving	I:C0917927
surgery	I:C0917927
(	O
not	O
mastectomy	O
)	O
,	O
provided	O
they	O
receive	O
whole	O
breast	I:C3897169
irradiation	I:C3897169
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

These	O
results	O
support	O
the	O
omission	O
of	O
a	O
radical	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
at	O
least	O
for	O
pN	O
+	O
patients	O
scheduled	O
for	O
breast	B:C0917927
-	I:C0917927
conserving	I:C0917927
surgery	I:C0917927
(	O
not	O
mastectomy	O
)	O
,	O
provided	O
they	O
receive	O
whole	O
breast	I:C3897169
irradiation	I:C3897169
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

These	O
results	O
support	O
the	O
omission	O
of	O
a	O
radical	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
at	O
least	O
for	O
pN	O
+	O
patients	O
scheduled	O
for	O
breast	O
-	I:C0917927
conserving	I:C0917927
surgery	I:C0917927
(	O
not	O
mastectomy	B:C0024881
)	O
,	O
provided	O
they	O
receive	O
whole	O
breast	I:C3897169
irradiation	I:C3897169
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

These	O
results	O
support	O
the	O
omission	O
of	O
a	O
radical	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
at	O
least	O
for	O
pN	O
+	O
patients	O
scheduled	O
for	O
breast	O
-	I:C0917927
conserving	I:C0917927
surgery	I:C0917927
(	O
not	O
mastectomy	O
)	O
,	O
provided	O
they	O
receive	O
whole	B:C3897169
breast	I:C3897169
irradiation	I:C3897169
and	O
guideline	O
-	O
adherent	O
adjuvant	O
systemic	I:C0677850
therapy	I:C0677850
.	O

These	O
results	O
support	O
the	O
omission	O
of	O
a	O
radical	O
axillary	O
lymph	I:C0193867
node	I:C0193867
dissection	I:C0193867
at	O
least	O
for	O
pN	O
+	O
patients	O
scheduled	O
for	O
breast	O
-	I:C0917927
conserving	I:C0917927
surgery	I:C0917927
(	O
not	O
mastectomy	O
)	O
,	O
provided	O
they	O
receive	O
whole	O
breast	I:C3897169
irradiation	I:C3897169
and	O
guideline	O
-	O
adherent	O
adjuvant	B:C0677850
systemic	I:C0677850
therapy	I:C0677850
.	O

